Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA alkylation at the O6 position of guanine refers to the covalent modification of the oxygen atom at the sixth position on guanine bases in DNA, most commonly by methyl or other alkyl groups. This lesion is primarily induced by exposure to certain chemotherapeutic agents (e.g., temozolomide) and environmental carcinogens. The resulting adduct, such as O6-methylguanine (O6MeG), is highly mutagenic and cytotoxic. If not repaired before replication, these lesions are recognized by the mismatch repair (MMR) system. MMR attempts futile cycles of repair on O6MeG:T mismatches, which can result in DNA double-strand breaks (DSBs). These DSBs trigger apoptosis.
Induction of O6-methylguanine leading to futile mismatch repair cycles and apoptosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA alkylation at O6 position of guanine leading to apoptosis (O6-alkylguanine).